(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2018 ending October 31, 2017.
- 0 Comments
- FY2018